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As there are reports in the literature  (1 a-d,  2) that highly purified gelatin 
is non-antigenic,  this substance and some of its chemical derivatives have been 
suggested and tested as possible blood plasma expanders (3). One of the gelatin 
derivatives which has been proposed is oxypolygelatin (OPG)  1 (4). The recent 
observations of Kabat and  Berg  (5)  and Maurer  (6)  that  dextran,  another 
plasma expander,  although  non-antigenic  in the rabbit,  is a  good antigen  in 
man led to the testing of the antigenicity of OPG in man. The results presented 
in this paper show that gelatin and its derivatives indeed are antigenic in man. 
The quantitative immunochemical data used to support this thesis  and some 
of the implications of these findings  in man  will be the subject  of this first 
paper. 
EXPERIMENTAL 
Antlge~.---Oxypolygelatins (OPG).  The  clinical OPG  tested  was  kindly  furnished  by 
Dr. Arthur Cherkin of Don Baxter, Incorporated, of Pasadena.  It wasLot No. S 230 X  and 
had an average molecular weight of about 27,000.  The molecular weight distribution as de- 
termined by Dr. J. W. Williams was as follows: 10,000,  16 per cent; 10,000-20,000,  33 per 
cent; 20,000-40,000,  33 per cent; 40,000-50,000,  12 per cent; 60,000-80,000,  4 per cent; 80,000- 
100,000,  1 per cent;  >  100,000,  1 per cent. 
The "high molecular weight" fraction of OPG S 230 X  was obtained by precipitation with 
two volumes of methanol. This preparation had an average molecular weight of 36,000, based 
upon  correlation  of  viscosity  and  osmotic  pressure  measurements. 
Gelatin Lot No. 2160  was also obtained from Don Baxter, Incorporated.  This was the 
material used to prepare the above OPG preparations.  It had a number average molecular 
weight of 50,000-75,000.  All of the above materials were found to be non-pyrogeulc and non- 
antigenic in  the guinea pig. 
* This investigation was supported  by a  grant from the Office of the Surgeon General, 
Department  of the Army contract  No.  DA-49-007-MD-248  upon  recommendation  of  the 
Subcommittee  on  Shock  of  the  National  Research  Council. 
:~ Presented in part before the 6th International Congress of Microbiology, Rome, Italy, 
September, 1953, and before the annual meeting of the American Association of Immunolo- 
gists, Atlantic City, April 12-17,  1954. 
This is reprint No. 34 of the Department of Pathology, University of Pittsburgh School 
of Medicine. 
10PG stands for oxypolygelatin. 
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Nitrogen analyses of the various protein antigens were performed by the Markham modi- 
fication of the micro Kjeldhal procedure  (7). All antigen solutions were adjusted to pH 7.5 
and preserved with 1/10,000 merthiolate. 
Immunization Procedure.--Healthy  medical volunteers were used. An initial preimmuniza- 
tion sample of 50 ml. of blood was taken. Each subject then received two intracutaneous tests 
with about 0.01  to 0.02 ml. of the OPG or gelatin preparation used for immunization con- 
taining 0.25 per cent phenol and a control of 0.85 per cent saline and phenol. After 15 minutes 
TABLE  I 
R~po~e ~Huma~ ~  Inj~tions~ ~in~  Oxypolygdatm $230 X 
Subject 
DAV 
DJF 
CAB 
jz 
JAC 
DGC 
JHA 
NS 
HJ 
PHM 
LH 
TCH 
WJH 
RNL 
CHL 
SW 
RAP 
TBL 
RRB 
JRL 
No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
OPG solution 
injected 
(9  injections) 
I 
Preinjection  I  3 weeks post injection 
~g. antibody N precipitated per mL of serum from 
3 mL serum treated with 
3gg. OPGN  9gg. OPGN  3~s. OPGN  9gg. OPGN 
0.0 
1.0 
0.2 
1.3 
0.3 
1.8 
0.8 
0.7 
1.1 
0.0 
0.1 
0.8 
0.6 
0.0 
0.6 
0.8 
0.8 
0.5 
1.1 
0.2 
0.5 
2.0 
1.0 
2.7 
0.8 
3.3 
3.4 
3.1 
6.7 
0.0 
1.3 
3.1 
6.4 
3.4 
3.6 
2.0 
3.1 
4.0 
0.2 
0.4 
1.5 
2.0 
2.2 
3.3 
0.8 
1.9 
1.9 
2.2 
1.5 
2.3 
0.8 
1.4 
0.0 
0.1 
3.6 
3.5 
mg./r,d. 
2 
2 
2 
2 
2 
5 
5 
5 
5 
$ 
10 
10 
10 
10 
10 
23 
25 
25 
25 
25 
4.4 
12.2 
4.6 
6.0 
3.9 
7.5 
2.9 
7.5 
4.7 
3.6 
2.7 
4.3 
10.3 
3.3 
3.7 
9.4 
the skin reactions were read. For the initial study with OPG the volunteers were divided into 
four groups. Each group received nine daily injections of clinical OPG containing 2, 5, 10, or 
25 rag. protein per ml. of solution. 3 weeks after the last injection a second 50 ml. sample of 
blood was  obtained and intracutaneous tests performed.  Half liter portions of blood were 
obtained  from  those  individuals who  showed  good  antibody  responses. 
For the repeat experiment additional medical volunteers were divided into three groups 
of seven per group. The groups received nine daily injections containing 25 rag. per injection 
of either OPG S 230 X, high molecular weight OPG or gelatin. Post-immunization bleedings 
were taken 3 and 7 weeks after the last injection. 4 months later the best antibody producers 
in each group were reinjected twice with 10 ms. of the appropriate antigen. 3 weeks after 
the last injection 500 ml.  portions of blood were again obtained. All serum samples were PAUL  H.  MAUI~ER  499 
handled with sterile precautions, and in addition merthiolate to a  concentration of 0.01  per 
cent and phenol to 0.25 per cent added. 
Quantitative Pre~ipitin Studies.--The  pre-  and  postimmunization sera  were  assayed  for 
antibody N  by the quantitative precipitin method of Heidelberger and MacPherson (8) using 
the  Folin-Ciocalteu tyrosine reagent  (9),  standardized  against known  amounts of  normal 
human  gamma  globulin  (fractions  II))  The  complete  method  is  repeated  here.  After 
remaining in the icebox for about 10 days,  each serum sample was centrifuged in the cold 
overnight, the lipid removed from the top, the serum decanted, and recentrifuged until per- 
fectly clear before use. In the initial studies with clinical OPG 3.0 ml. portions of pre- and 
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FIG. 1.  Calibration curves of human antiserum (RRB.).  0, clinical OPG;  A, fractionated 
OPG;  e,  pigskin gelatin. 
postimmunization sera were measured into 8  ml. centrifuge tubes calibrated at the 2.5 ml. 
mark. 3 and 9 #g.  of OPG nitrogen in a  volume of 1.0 ml. were added to successive tubes. 
The addition of 1.0 ml. of saline to 3.0 ml. of serum served as the serum control. The tubes 
were mixed, capped, placed in a  water bath at 37°C.  for 1 hour and in the refrigerator for 
from 10 to 14 days with mixing of the tubes daily. The tubes were centrifuged in the cold 
and the precipitates were washed three times with chilled saline. The dissolution of the pre- 
cipitates with 0.5 ~  NaOH at 37°C.  was very time consuming. It was later observed that 
warming the precipitates to  50°C.  resulted in immediate solution. This was in accordance 
with some of the known properties of gelatin which, as will be shown later, was in the pre- 
cipitate; namely, to dissolve readily upon warming to about 50°C.  The dissolved precipitates 
were made up to the 2.5 ml. mark and 2,0 ml. aliquots analyzed by the Folin-Ciocalteu method 
at  7500 A  using a  Beckman model DU spectrophotometer.  (Table I). 
s The author wishes to thank Dr. E. A. Kabat for supplying him with this preparation. 500  ANTIGENICITY  OF  OXYPOLYGELATIN  AND  GELATIN  IN  MAN 
TABLE  II 
Response  of Human  Volunteers  to Injection  of Oxypolygelatin  S  230  X  (Group  1)* 
Preimmunization absorption  3absorption~mUnizationWk.  pestim- 
]st  __  7nd  3rd 
Anti- [  Anti-  , Anti-  Anti- 
body  ] body  I body  body 
Anti  n  N  I--..  I N  Antigen l N  N"  e  ~g  en  N  ad  ~o~  pre-  ]~ ngal~  I pre-  added  [ pre-  Antigen  Rre.- 
,~r ~-~  cipi-  "'..f."~  ' cipl-  N  per  cipi*  N  added 
r ....  tJ~t ~A.  se-  rated  _  tared  ml.  tared  per mL  cipl-  tared 
trait  per  ~rmtt  per  serum  per  serum  per 
ml.  ml.  ml.  ml. 
serum  serum  serum  serum 
jsS.  #g.  /~g.  ttg.  it&.  jag. 
RWHI 21  1.I OPG  1.0  5.6OPG  2.7  1.9  3.9OPG 
3.3  "  3.8  --  --  6.5  3,0 
4.1 gel  14.711 3.0 gel  4.8 
7 wk. l~ostimmunization 
absorption 
1st  2nd§ 
Anti-  Anti- 
Antigen  bN°dy  ~NdY 
N  added  p  re*  Antigen N  l~..e- 
clpl- added per  clpl- 
per  ml.  tated ml. serum  tated 
serum  ~  per 
ml. 
serUnl  serllm 
~g.  ~g.  ~g.  ;zg.  ~g. 
1.6  I.IOPG  ,5.4  1.0 gel  7.2 
,5.8*  3.4  "  13.4  t.0  "  3.1 
2.0 gel  19.5  2.0 HOPG  2.0 
3.1  "  22.2  2.0  "  0,0 
0.0  1.10PG  1.8  1.0gel  0.0 
3.2  3.4  ,c  4.3  1.0  "  0.0 
2.0 gel  7.6  2.0HOPG  0.0 
3.1  "  7.2  2.0  "  0.0 
0.0  1.1OPG  4.6  1.0 gel  5.3 
3.0  3.4  "  10.7  1.0  "  3.5 
4.8  2.0 gel  19.0  2.0HOPG  0.0 
4.1  "  17.8  2.0  "  0.0 
0.0  1.1OPG  2.2  1.0 gel  3.6 
4.0  3.4  "  6.7  1.0  "  2.4 
2.0 gel  11.8  2.0HOPG  0.0 
4.1  "  12.8  2.0  "  0.0 
0,0  1.1OPG  2.0  1.0 gel  2.2 
0.8  3.4  "  3.3  1.0  "  0.7 
2.9  2.0 gel  9.0  2.0HOPG  0.0 
4.1  "  6.3  2.0  "  0.0 
1.8  1.1OPG  3.3  1.0 gel  3.7 
4.3  3.4  "  6.6  1.0  "  2.3 
8.8  2.0 gel  12.6  2.0HOPG  0.0 
4.1  "  11.0  2.0  "  0.0 
4.3  1.10PG  3.3  1.0 gel  3.5 
8.8  3.40PG  2.2  1.0  "  2.2 
2.0 gel  11.5  2.0HOPG  0.0 
4.1  "  11.5  2.0  "  0.0 
AK  22  1.1OPG  0.7  5.6OPG  6.3  1.9  3.9OPG 
3.3  "  5.2  --  --  6.5  3.0 gel 
4.1 gel  11.511  -- 
HM  23  1.1OPG  1.2  5.6OPG  3.3  3.7  1.1OPG 
3.3  "  4.5  --  --  6,6  4.2  " 
4.1 gel  10.011 3.0 gel  4.3  3,0 gel 
HH  24  i 1.10PG  --  S.6OPG  1.0  3.0  4.2OPG 
3.3  "  3.0  5.0  3.0 gel 
4.1 gel  8.8[[  3.0 gel  6.1 
TH  1.1OPG  0.5 ,]  $.6OPG  1 0.4  1.6  I.I  OPG 
3.3  "  1.4  :  7.7  4.2  " 
4.1 gel  5.911 3.0  gel  3.7  3.0  gel 
JB 
JF 
26  1.10PG 
3.3  " 
4.1 gel 
1.10PG 
3.3  " 
4.1 gel 
0.7  15.6OPG]  1.6 
4.7 
'  I 
1 
I 
0.0  $.6OPG:  0.0 
0.2  3.0 gel  4.211  4.8 
2.1  1.10PG 
3.9  4.2  " 
3.0 gel 
3.5  4.20PG 
0.8  3.0 gel 
* 3.0 ml. used for analyses except where noted. 
Only 1st absorption values reported  here. 
§ Results of a  3rd absorption with clinical OPG were negative. 
I[ 1.5 ml. used for analysis. 
In  the  repeat  study  when  three  different  antigens  were  used  for  immunization,  the  pre- 
immunization  sera  were  analyzed  as  follows:  Group  1--(clinical  OPG);  to  3.0  ml.  aliquots 
3.4 and  10.1  pg. OPG  N  were  added.  After  incubation  and  centrifugation  as described  above, 
the  supematants  were  absorbed  successively  with  clinical  OPG  and  gelatin.  Additional  ali- 
quots  were  absorbed  initially  with  gelatin. PAUL  H.  MAURER  501 
TABLE  III 
Response of Human  Volunteers to Injection of High Molecular  Weight OPG S  230 X 
(Group 2)* 
CB  31 
JF  32 
CT  33 
FK  34 
RSS  35 
CLK  36 
RB  37 
Preimmunizatlon absorption 
3 wk. ~ostim-  mumzation  7 wk. postlmmunization 
absorption~  absorption 
1st  2nd  8rd 
•  ~,~  •  i~,~  ~,~  .  ~,~ 
I 
t~g.  /~g.  ~t.  t*g.  #g.  t*g.  t~g.  t~g. 
1.1HOPG  6.6  1.7HOPG  7.2  1.0gel  1.9  1.THOPG  6.5 
I  3.8  "  15.3  1.7  "  1.9  1.5  "  0.3  5.6  "  7.7 
4.1 gel  15.8ll  3.0 gel  4.~  2.8 gel  9.0 
1.1HOPG  6.1  1.THOPG  3.C  1.0gel  2.5  1.7HOPG 
3.8  "  13.9  1.7  "  2.2 1.5  "  1.0  5.6  " 
4.1gel  ! 15.5~  3.0gel  5.3  2.8gel 
1.1HOPG  2.8  1.THOPG  2.4  1.0gel  0.6  I.THOPG  5.4 
3.8  "  4.5  1.7  "  0.1  1.5  "  0.8  5.6  "  3.3 
4.1 gel  5.81[  3.0 gel  2.0  2.8 gel  5.5 
1.1HOPG  4.5  1.THOPG  4.4  1.0gel  1.4  1.THOPG  10.9 
3.8  "  8.4  1.7  "  0.4  1.5  "  0.5  5.6  "  14.6 
4.1 gel  8.8[[  3.0 gel  2.6  2.8 gel  13.4 
1.1HOPG  4.9  1.THOPG  7.7  1.0gel  1.8  I.THOPG  9.6 
3.8  "  12.5  1.7  "  1.4  1.5  "  0.7  5.6  "  10.2 
4.1 gel  13.3[[  3.0 gel  2.6  2.8 gel  11.0 
1.1HOPG  4.4  1.THOPG  4.6  1.0gel  1.4  1.7HOPG  5.3 
3.8  "  9.3  i 1.7  "  0.4  1.5  "  0.0  5.6  "  6.4 
4.1 gel  9.9[]  3.0 gel  3.8  2.8 gel  8.5 
1.1HOPG  4.8  1.7HOPG  4.6  1.0gel  1.0  1.7HOPG 
3.8  "  9.6  1.7  "  0.6  1.5  "  0.0  5.6  " 
4.1 gel  8.8[[  3.0 gel  4.8  2.8 gel 
Ist  2nd§ 
•  RE  ' e 
1.7 HOPG  8.71 2.0HOPG  2.~ 
2.8  "  10.I  2.0  "  1A 
2.0 gel  10.3  1.0 gel  ~ 0.¢ 
4.1  "  7.2  I 
9.3  1.THOPG10.2  2.0HOPG  3.( 
13.1  2.8  "  13.8  2.0  "  ,  2.1 
12.3  2.0 gel  13.5  1.0 gel  I.~ 
4.1  "  10.6 
1.THOPG  8.8  2.0HOPG  2.$ 
2.8  "  10.9  2.0  "  0.3 
2.0 gel  11.2  1.0 gel  1.4 
4.1  "  9.3 
I.THOPG  9.5  2.0HOPG  1.$ 
2.8gel  12.6  2.0  "  2.~ 
2.0  "  12.1  1.0 gel  2.2 
4.1  "  11.7 
! 
2.9  1.THOPG  i 5.7  2.0HOPG  1.I 
1.5  2.8  "  6.1  2.0  "  0.7 
2.6  2.0gel  8.5  1.0gel  1.1 
4.1  "  I  5.0 
* 3.0 mL used for analyses except where noted. 
Only 1st absorption values reported here. 
§ Results of a  third absorption with clinical OPG were negative. 
[I 1.5 ml. used  for analysis. 
Group  2  (high molecular  weight  OPG).  3.0 ml. aliquots  were set up with  3.3 and  11.4 ~g. 
N  fracfionated  OPG.  The  supematants  were successively absorbed  with five ~g. fmctionated 
OPG  N  and  3  to 4.5 ~g. gelatin N. Here,  too,  additional  aliquots were absorbed  with  gelatin. 
Group  3  (gelatin). 3.0 ml aliquots were set up with 4.1 and 8.3 ~g. gelatin N. After analysis 
of  the  precipitates,  the  supernatants  were  absorbed  with  8.3  and  4.1  ~g.  gelatin  N  respec- 502  ANTIGENICITY OF  OXYPOLYGELATIN AND  GELATIN ~  MAN 
TABLE  IV 
Respons~  of Human  Volunteers  to Injection  o/Gelatin  L  2160" 
°~  . 
[D  41 
~-I  42 
43 
RD  44 
RC  45 
EH  46 
RB  47 
3 wk. postim- 
Preimmunization absorption  munization  7 wk. postimmunization 
absorption~  adsorption 
1st  2nd  3rd  1st  2nd§ 
Anti*  Anti-  Anti-  Anti-  Anti-  Anti- 
b~y  in~gen  b~dy  b#y  Antigen  bN~Y  bN~tY  AriSen  b°~NY 
p.re-  p.re-  Antigen N  p.r.e-  N added  pre-  Antigen N  pre-  p.reT. 
cxpl-  added  clpi-  added per  clpt-  cipi-  added per  cipi-  added  ctpxo 
tared  per ml.  tared  ml. serum  tared  per m/.  rated  ml. serum  tared  per cal,  tat(x]  serum  per  serum  per  per  per  per  serum  per 
ml.  ml.  mL  mL  ml.  mL 
~eru£fl  3erum  serunl  ~erum  8eruln  seffttl~ 
Antigen 
N added 
per mL 
serum 
/=g. 
1.4 gel 
2.8  " 
4.50PG 
11.9  2.8 gel  3.2  4.20PG  0.0  3.1 gel  6.2  2.0 gel  10.0  1.0  gel  1.5 
13.1  1.4  "  0.9  3.3HOPG  0.0  5.5  "  6.3  4.1  " 
6,211  4.2OPG  3.5  3.30PG  5.5  1.0gel  0.0 
2.SHOPG  9.6  1.0  "  0.0 
1.4 gel  6.7  2.8 gel  0.0  4.20PG  0.0  3.1 gel  6,9 
2.8  "  6.8  1.4  "  0.0  3.3HOPG  0.0  5.5  "  7.5 
4.50PG  3.011  4.20PG  4.8 
1.4 gel  9.7  2.8 gel  2.1  4.20PG  0.0  3.1 gel  7.9  2.0 gel  10.0  1.0 gel  3.1 
2.8  "  11.5  1.4  "  0.8  3.3HOPG  0.0  5.5  "  8.5  4.1  "  12.3  1.0  "  3.2 
4.5OPG  4.0[[  4.2OPG  4.2  3.3OPG  4.5  1.0  "  3.5 
2.8HOPG  12,2  1.0  "  1.5 
1.4 gel  12.1  2.8 gel  2.4  4.2OPG  0.0  3.1 gel  8.9  2.0 gel  13.1  1.0 gel  3.6 
2.8  "  13.1  1.4  "  1.2  3.3HOPG  0.0  5.5  "  9.1  4.1  "  11,2  --  -- 
4.50PG  5.5[l  4.2OPG  5.8  3.30PG  6.1  1,0 gel  1.9 
2.8HOPG  15,7  1,0  "  0.0 
1.4 gel  6.3  2.8 gel  0.4  4.2 OPG  0.0  3.1 gel  8.5  2.0 gel  8.8  1.0 gel  1.7 
2.8  "  6.9  1.4  "  0.0  3.3HOPG  0.0  5.5  "  8.5  4.1  "  6.8  --  -- 
4.50PG  2.9[]  4.2  "  4.6  3.30PG  3.8 
2.SHOPG  8.9 
1.4 gel  10.4  2.8 gel  2.6  4.20PG  0.0  3.1 gel  3.1  2.0 gel  9.5  1.0 gel  2.4 
2.8  "  11.5  1.4  "  0.9  3.3HOPG  0.0  5.5  "  3.0  4.1  "  7.4  --  -- 
4.5OPG  4.511  4.2  "  2.1  3.3OPG  3.6  1.0gel  3.5 
2.SHOPG  9.6  1.0  "  0.4 
1.4 gel  12.7  2.8 gel  3.7  4.20PG  0.0  3.1 gel  3.9  2.0 gel  9.0  1.0 gel  0.9 
2.8  "  16.5  1.4  "  1.9  3.3HOPG  0.0  5.5  "  4.7  4.1  "  7.3  1.0  "  0.2 
4.50PG  5.911  4.2  "  2.8  3.30PG  3.2  1.0  "  2.4 
2.8HOPG  9.2  1.0  "  0.0 
* 3.0 ml. used for analyses except where noted. 
~; Only 1st absorption values reported here. 
§ Results of a 3rd absorption with clinical  OPG were negative. 
1.5 mL used for analysis, 
tively, followed by absorption with either clinical OPG or high molecular weight OPG. Once 
again this procedure was repeated initially using clinical OPG. 
The data giving the amounts of antigen added to the original serum and supematant  for 
each analysis and the antibody N  precipitated during each absorption for the pre-, and the 
3,  and  7  week postimmunization bleedings are given in Tables II  to IV. PAUL  H.  MAURER  503 
Quantitative precipitin curves (9) were set up with the sera obtained from those volunteers 
who had shown the best antibody responses. The sera were calibrated using all three antigens 
irrespective of the one used for immunization. Tables V and VI show the data with the sera 
from subject 19 and the pool in Group 1. 
TABLE  V 
Anlibody Nitrogen Precipitated by Gdatin and Its Derivatives  from 3.0 ml. 
Human Au2iserum (Anli-OPG) from Subjea RRB, no. 19 
OPG N added 
per ml. serum 
2.3 
3.4 
5.6 
8.5 
11.3 
16.9 
Antibody N 
precipitated 
petrol serum 
1.4 
2.0 
4.5 
2.7 
2.6 
1.4 
HOPG N added 
per ml. serum 
/tg. 
0.5 
1.1 
2.2 
3.6 
5.4 
24.4 
Antibody N 
precipitated 
per m~. serum 
/~g. 
2.1 
4.4 
7.0 
8.2 
8.3 
6.7 
Gel N added 
per ml. serum 
1.4 
2.8 
5.5 
11.0 
16.5 
55.0 
Antibody N 
precipitated 
per ml. serum 
7.5 
10.9 
11.3 
11.2 
6.4 
1.0 
TABLE  VI 
Antibody Nitrogen Precipitated by Gdcgin and Its Derivatives  from Human 
Anaserum (C,  roup 1) 
Antibody N  Antibody N  Antibody N  OPG N added  precipitated  HOPG  N added  precipitated  Gel N added  precipitated  per mL serum*  per ml. serum:~  per nd. serum~ 
per nu. serum  per zm. serum  per mh serum 
0.7 
1.9 
2.8 
4.2 
7.0 
11.3 
16.9 
28.2 
33.7 
56.4 
1.0 
4.5 
6.0 
7.7 
10.2 
11.1 
10.4 
7.5 
4.3 
0.6 
0.9 
1.9 
3.5 
5.6 
8.4 
13.4 
28.0 
54.2 
67.6 
1.4 
6.7 
10.9 
15.5 
15.1 
10.4 
7.5 
0.0 
0.0 
/~&. 
0.7 
2.0 
4.0 
5.5 
8.3 
13.7 
27.5 
41.3 
69.3 
3.6 
14.0 
16.5 
16.0 
15.4 
14.2 
12.5 
12.0 
9.6 
* 3.0 ml. serum used for each analysis. 
~; 1.5 ml. serum used for each analysis. 
Hydroxy~oline  Andysis.--In order to measure the OPG and/or gelatin incorporated into 
the specific precipitates advantage was taken of the high concentration of hydroxyproline in 
gelatin and its derivatives. The method of Neuman and Logan  (10)  was employed.  Addi- 
tional precipitates,  in  triplicate, were  analyzed  along with standards of both gelatin and 
hydroxyprolinO each time. This was necessitated by the fact that the hydroxyprollne curves 
were  not  the  same  each  day.* 
* The hydroxyproline standards were made from the material supplied by Pfanstiehl Chem- 
ical Co.,  Waukegan, Illinois. 
4Similar  observations have  been  noted  by  others  (11). 504  ANTIGENICITY  OF OXYPOLYGELATII~ AND  GELATIN IN M-AI~ 
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Although hydroxyproline analyses were performed on many precipitates obtained with 
preimmunization sera the values presented in Table VII and Figs. 2 and 3 refer only to the 
postimmunization  sera. 
Solubility  of Specific Precipilalcs.--In  order to determine the solubility of gelatin-anti- 
gelatin precipitates in excess antigen additional precipitates were formed. They were washed 
as described above and then resuspended overnight at room temperature in either 1.0 ml. of 
gelatin,  formallnized gelatin,  modified fluid gelatin,  5 bovine serum  albumin, 6 ovalbumin,  7 
containing 1 nag. N/ml. or in 1 ml. of 0.9 per cent NaCI which served as the control. The 
precipitates were then centrifuged, washed with chilled saline, dissolved to 2.5 ml. and 2.0 ml. 
TABLE VII 
Analysis of Precipitates from Croup 2 Serum 
Antigen N added 
permL serum 
OPG  1.1 
2.8 
5.6 
7.1 
HOPG  1.1 
3.5 
5.6 
8.4 
11.2 
GEL  1.1 
2.8 
5.5 
8.3 
Antigen N 
precipitated from 
hydroxyprollne data 
ttg. 
0.4 
0.7 
1.2 
1.5 
0.7 
2.2 
2.4 
2.9 
2.1 
0.7 
1.3 
1.9 
3.0 
for Presence of Antigen 
Antigen precipitated 
36 
25 
22 
21 
Antibody N 
precipitated (from 
preclpitin curves) 
1.5 
2.7 
4.1 
4.8 
Antibody N. 
precipitated 
precipitate 
4.1 
3.8 
3.4 
3.2 
66  4.0 
63  9.4 
43  10.4 
35  10.2 
18  8.2 
64  6.5 
47  12.7 
35  12.5 
36  11.0 
5.6 
4.3 
4.3 
3.5 
3.9 
9.3 
9.8 
6.6 
3.7 
aliquots taken  for analysis of the tyrosine color produced by the Folin-Ciocalteu method. 
The results were conclusive that the precipitates dissolved only in gelatin or formalin-treated 
gelatin. 
Rabbit Ana-HGG.--Antisera against human gamma globulin were obtained by immuniza- 
tion of rabbits  with tither  Cutter's  s or Lederle's  ° immune serum globulin as described  in 
previous publications  (12). 
Resuspension of Specific Precipilates in Anti-HGG Sera. One of the methods used  to sub- 
stantiate  the fact that  the protein being precipitated by gelatin and/or its derivative was 
indeed antibody  (gamma globulin) was to resuspend  precipitates in rabbit anti-HGG sera. 
Gelatin-antigelatin precipitates  were  formed  by adding  increasing amounts  of gelatin  to 
Kindly  furnished  by  Dr.  D.  Tourtellotte  of  the  Knox  Gelatin  Company,  Camden, 
New Jersey. 
6 Armour recrystaUized BSA Lot No.  128-75, The Armour Laboratories,  Chicago. 
Prepared according to reference 25. 
8 Cutter Laboratories, Berkeley, California. 
Lederle Laboratories Division, American Cyanamid Company, Pearl River, New York. 506  ANTIGENICITY  OF  OXYPOLYGELATIN" AND  GELATIN" It~  MAN" 
varying volumes of human antigelatin sera. The precipitates which formed were washed  six 
times to eliminate the slightest possibility of any serum proteins remaining adsorbed to the 
precipitates. The precipitates  were then resuspended in 1.0 ml. of the rabbit anti-HGG serum 
at 5°C. Additional precipitates were resuspended  in 1.0 ml. of normal rabbit serum which 
served as the respective controls. Both the normal rabbit serum and rabbit anti-HGG were 
decomplemented  to remove the possibility  of complement N interfering with the results (13). 
After 8 days in the refrigerator, during which time the precipitates were resuspended  twice 
daily, the tubes were  centrifuged  and washed  as mentioned  above. The precipitates were 
dissolved and analyzed for Folin color at 7500 A as described above. The results are given in 
Table VIII. 
Passive Transfer  (Anaphylaxis)  Sludies.--Eight  ml. of human serum  containing 5 t~g. of 
antibody (antigelatin) N per ml. were injected into each of six guinea pigs weighing about 
250 gin.  (14). A "shocking" dose of 1 ml. of gelatin containing 1 rag. N" was injected intra- 
TABLE VIII 
Optical Density at 7500 A of Gdatin-Antigelatin  (Human) 
Resuspended in 
Normal rabbit serum  Rabbit Anti-HGG  sera 
0.028  0.040 
0.141  0.190 
0.154  0.250 
O. 205  0.300 
venously 48 hours later. As no anaphylaxis ensued the guinea pigs were injected with 60 ~g. 
of rabbit antibody N  against BSA. This was to see whether the guinea pigs were refractory 
The challenging dose of BSA was 1 rag. 
RESULTS 
Table I  summarizes the results obtained in 20 individuals in the initial study 
involving clinical OPG.  In all the data presented the exceedingly small con- 
tribution of Folin color given by gelatin or its derivatives has been neglected 
in calculating antibody values. Analyses of varying concentrations of gelatin 
and  OPG  were  performed by the Folin-Ciocalteu method.  As was  to  be ex- 
pected, owing to the virtual absence of tyrosine in the proteins, insignificant 
optical densities were obtained. 
Quantities of antibody nitrogen below 2 #g. per ml. are not considered sig- 
nificant. The data in the preimmunization sera show that 13 of the 20 volunteers 
(65 per cent) had significant amounts of protein precipitable by OPG.  In 13 
of the postimmunization sera  the precipitable antibody had  increased by at 
least 2 #g. N. In one instance (No. 2) there was a  rise in antibody N  from 2 to 
12 #g. per ml. In 3 sera there was no significant change in antibody level whereas 
one subject actually showed a  decrease in antibody level. Three of the post- 
immunization  sera  were  lost.  There  were  no  marked  skin  reactions  (wheal 
and erythema type) either before or after immunization. The concentration of PAUL ft.  ~.Am~.sR  507 
OPG injected (2 to 25 mg./ml) had no effect on the magnitude of the antibody 
response.  It was somewhat surprising  to find antibody present  in  the pre- 
immunization sera. The possible sources of this antibody will be discussed later. 
The sera of the 500 ml. bleedings obtained from the volunteers (Nos. 2, 6, 
13, and 19) were calibrated with clinical OPG, the fractionated OPG and gela- 
tin. Only the data obtained with No. 19 is presented as it was quite representa- 
tive of the others. From Table V and Fig. 1 it is quite evident that we are deal- 
ing with a protein--antiprotein system. The shapes of these curves and those 
to be presented later are typical of a polydisperse  and/or denatured antigen. 
(For complete  discussion  of this see reference 9). The precipitation of anti- 
body from the serum by the different antigens increased  with the molecular 
size of the antigen; i.e.,  gelatin precipitated more antibody than did  frac- 
tionated OPG which in turn precipitated more antibody than did clinical OPG. 
This will be reiterated in the results obtained in the repeat experiment. 
Tables II, III, and IV present the results of the many analyses of the three 
different groups of volunteers used in the repeat experiment.  Group  1 was in- 
jected with clinical OPG, Group 2 with the fractionated (high molecular weight) 
OPG,  and Group  3, was injected with the gelatin from which the OPG was 
made. For the sake of clarity and to avoid generalization  it is best to present 
the results of each group separately. 
Group 1.  The analyses of the preimmunization sera  with OPG and gelatin 
indicate that gelatin precipitates much more antibody than does clinical OPG. 
Although the absorption of the supernatants from the  OPG tubes with more 
OPG precipitates more antibody, still there is considerably less antibody pre- 
cipitated than by the gelatin alone.  In  most cases small amounts of gelatin 
added to  the second  supernatant precipitated  additional antibody. Of con- 
siderable interest is the fact that the total antibody N precipitated in two ab- 
sorptions  with OPG  (1.1 #g.  OPG N/ml.  serum  followed  by 5.6  #g.  OPG 
N/ml) is equal,  within experimental  error,  to the amount precipitated by 3.3 
#g. OPG N/ml. serum originally. 
In most cases  two  absorptions  with gelatin precipitate significantly  more 
antibody than did the OPG plus small concentrations of gelatin.  A third ab- 
sorption  of the sera  analyzed with gelatin with OPG gave insignificant pre- 
cipitates. 
The results obtained on the 3 week postimmunization bleedings were some- 
what surprising in that five out of the seven individuals had a lower antibody 
level than before injection of OPG. Further bleedings were therefore taken at 
the time the 3 week bleeding values were obtained. This, in all cases, was 7 
weeks after the last injection.  For brevity, only the results of two absorptions 
will be presented for the 7 week postimmunization bleedings. Of the five indi- 
viduals who showed decreased antibody in the 3 week postimmunization bleed- 
hags four had significant increases in antibody N  on the 7 week bleedings. 
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and gelatin indicate that gelatin precipitates only a few more ~g. of antibody 
N  from the various sera than does the fractionated OPG. Moreover here  too 
the total antibody precipitated by the absorption of antibody first with  1.1 
#g.N high molecular weight OPG followed by another precipitation with  1.7 
~g. N  fractionated OPG was equal to the amount of antibody N  precipitated 
by a single precipitation with 3.8 ~g. N fractionated OPG. 
The results on the 3  week postimmunization bleedings in this group also 
indicated that of the seven volunteers injected with fractionated OPG only 
one showed a  significant increase over the preimmunization antibody levels. 
Three showed a  significant decrease and three did not change significantly in 
their antibody values. 
Of the five volunteers from whom serum was obtained 7 weeks after the last 
injection two showed a significant increase and two showed a decrease in anti- 
body levels. Of interest is subject 32 who showed no significant change in anti- 
body level in any of the three bleedings. 
Group 3.--The analyses of the preimmunization sera with gelatin and clinical 
OPG again showed that gelatin precipitates more antibody than does clinical 
OPG.  The  total  antibody precipitated  by  the  absorption  of antibody first 
with 1.4 #g. gelatin N  followed by another absorption with 2.8/zg. gelatin N 
was equal  to the amount precipitated by 2.8/zg.  gelatin N  followed by  1.4 
#g. gelatin N. 
In only 1 individual (No. 45)  in the 3 week postimmunization bleeding was 
there any increase in antibody. No. 42 showed no change and all the others had 
decreases in antibody level. 
Of the six volunteers from whom serum was obtained at the 7 week bleed- 
ing three exhibited increases, two showed no change, and one still had antibody 
levels below the preimmunization values. 
The 7 week bleedings in this group were analyzed with gelatin, fractionated 
OPG,  and the clinical OPG.  In most cases the antibody N  precipitated by 
gelatin and the high molecular weight OPG were about the same whereas the 
clinical OPG precipitated ~  to ~/~ as much antibody as  the other antigens. 
It should be mentioned that in addition to the results on medical volunteers 
tabulated in this paper, similar results have been obtained in another 40 volun- 
teers. The serum from the 500 ml. bleedings of the two best reactors in each 
group  were  pooled  into  their  respective  groups.  Results  of  the  calibration 
curves obtained with the pools of Groups 1 and and 2 are presented in Figs. 
2 and 3. The data used to prepare Fig. 2 are presented in Table VI. From these 
data again it is fairly certain that one is dealing with a  protein-antiprotein 
system in which the antigen is polydisperse and/or denatured. That gelatin 
precipitates more antibody than the fractionated OPG,  which in  turn  pre- 
cipitates more than the clinical OPG, is further substantiated by these data. 
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doubt that the antigens were in the precipitates. Preliminary analyses of the 
precipitates from some of the preimmunization sera for hydroxyproline also 
indicated that gelatin was indeed in the precipitate. However, in order to get 
a  quantitative estimation of the amount of the added antigen which was in- 
corporated  into  the  precipitate,  additional  precipitates  were  analyzed  for 
hydroxyproline. The results presented in Table VII  (Group  1)  indicate that 
in antibody excess about 33 per cent of the OPG, 65 per cent of the fractionated 
OPG,  and about 65 per cent of the gelatin added are incorporated into the 
precipitates. Similar results were obtained with the other two pools of human 
serum. With Group 2 serum 80 per cent of the gelatin was incorporated into 
the precipitates in antibody excess. As all these antigens are polydisperse one 
can assume that those molecules of highest molecular weight are present in 
the  antigen-antibody  complex.  Similar  results  were  recently  obtained  by 
Kabat  et  al.  (15)  using  the  dextran-antidextran system.  When  the  clinical 
type and  fractionated dextrans containing C 14  were  added  to  human anti- 
dextran sera in the region of antibody excess 60 to 100 per cent of the added 
radioactivity was precipitated. 
From the amounts of antigen added to the serum the theoretical amount of 
antibody N which should be precipitated can be read off the calibration curves 
(9). This information allows a calculation of the antibody N/antigen N ratios. 
When the ratios of antibody N/antigen  N  in  the precipitates  were  plotted 
against the antigen N  in the precipitates fairly straight lines were obtained. 
The initial combining ratios (2R) of the different antigens with the Group 1 
serum were 8.3 for OPG, 10.2 for the fractionated OPG, and 13 for the gelatin. 
With the group 2 serum the 2R values were 4.4,  6.7,  and 11.7 respectively. 
That fairly straight lines were obtained would lend credence to the fact that 
one is dealing with a true antigen-antibody reaction. 
The gelatin anti-gelatin precipitates were soluble only in excess gelatin, thus 
fulfilling a  very important criterion of an antigen-antibody precipitate;  i.e., 
that it be soluble in excess antigen. The results obtained with the formalinized 
gelatin and modified fluid gelatin were  in  accord  with  unpublished  experi- 
ments from this laboratory on the cross-reactivities of various gelatin deriva- 
tives with antigelatin sera (16). As a complete report will be submitted shortly 
it is only necessary to  state here that formalinized gelatin cross-reacted  ex- 
tensively with antigelatin sera  whereas modified fluid gelatin did not react. 
That the protein precipitated with gelatin resembled human gamma globu- 
lin is suggested by the fact that the precipitates picked up additional protein 
material  from the  rabbit  anti-HGG serum  (Table  VIII).  Although offhand 
one might expect the gamma globulin in the gelatin-antigelatin precipitates 
would react with more antigamma globulin, it should be remembered that the 
gelatin may be masking some of the sites in the gamma globulin molecules 
which are capable of reacting with the antihuman gamma globulin molecules. 510  ANTIGENICITY  OF OXYPOLYGELATIN  AND  GELATIN IN MAN 
Additional proof  that  the  gelatin-antigelatin precipitates  contained gamma 
globulin was furnished by the ultraviolet absorption spectra of the dissolved 
precipitates  which resembled closely that of human gamma globulin. 
DISCUSSION 
Before discussing any of the implications of these findings on the antigenicity 
of gelatin in man the obvious question arises as to why had it not been observed 
heretofore. Previous investigations of this problem did not utilize the micro- 
precipitin techniques used in this study. Waksman and Mason  (2)  detected 
some increase in the nitrogen adsorbed on collagen particles when added to 
human sera. However, this increase was well within the limits of this method of 
analysis for nitrogen. In addition, complement fixation tests which were used 
by previous investigators would be of little value as there were no significant 
differences in the antibody levels before or after decomplementation with an 
ovalbumin  (Ea)-rabbit  anti-Ea  system  (17).  The  recent paper  of Watson, 
Rothbard, and Vanamee (18 a), which is a more intensive investigation of the 
work of Loiseleur and Urbain (18 b), indicates that rat collagen (acid-soluble 
form) is antigenic in rabbits. The method for estimation of the antibodies was 
complement fixation. It is quite possible that the collagen-anticollagen system 
fixes  complement whereas the gelatin-antigelatin precipitate does not.  From 
recent experiments in this laboratory there seem to be some immunochemical 
differences between gelatin and collagen. Another very likely possibility as to 
why no precipitation was observed before, is that in previously reported work 
the reaction was observed only for 48 hours. In most of the cases studied here 
precipitation of the antigen-antibody aggregates did not occur for 3 to 6 days. 
At this point it may be worth mentioning that the speed for precipitation was 
determined not only by the antibody level in the serum but also by the antigen 
added.  Gelatin,  in many cases  caused precipitation  overnight,  whereas  the 
clinical OPG set up at the same time did not precipitate for 4 to 5 days. With 
other sera the gelatin did not precipitate before 4 days. 
At this point it might be questioned whether or not we are measuring anti- 
bodies to gelatin or to some impurity in the gelatin. Although the presence of 
hydroxyproline  (gelatin)  in  the precipitates  should  be  conclusive evidence, 
further evidence was obtained through the use of gelatins from several species 
(16). These various gelatins were almost equally effective in precipitating anti- 
body from different sera. Complete data on these reactions will be presented 
in another communication. That all these gelatins would have the same im- 
purity is fairly unlikely. However the possibility that gelatin or its derivative 
is  cross-reacting with  antibody to  collagen or some degradation product of 
collagen  cannot  be  overlooked.  Experiments  are  underway  to  compare  by 
these  quantitative  immunochemical  techniques  the  "procollagens"  (soluble 
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The next question of importance is what is the source of the antibodies to 
gelatin in the pre- "immunization" sera. At least two possibilities exist. The 
individuals may produce antibody against the gelatin present in most diets or 
else the antibodies may be made to  the naturally occurring collagen in the 
connective tissue. It is quite plausible that by the action of certain enzymes 
collagen might be converted into a  gelatin-like substance which then can in- 
duce the formation of antibodies. In order to test these possible explanations 
it is hoped to analyze sera from the following type individuals: infants who 
have never been fed gelatin or meat products, true vegetarians, and individuals 
suffering from what has been  termed  "collagen" disease such as lupus ery- 
thematosis, disseminated  lupus,  rheumatoid  arthritis,  and rheumatic  fever, 
Although similar studies were  initiated by Waksman and Mason  (2),  their 
method of analysis was not sensitive enough to detect 20 gg. of antibody N. 
The data presented here to substantiate the fact that there are antibodies to 
gelatin in human sera may seem a  bit voluminous. However, it should be re- 
alized that one of the theories concerning the antigenicity of proteins has been 
based on the fact that gelatin could not be shown to be antigenic. The lack 
of tyrosine residues in the molecule (19),  the denatured state in which gelatin 
exists  (20),  and the high concentration of glycine which does not allow the 
molecule to attain a  rigid backbone structure (21) have been said to account 
for the non-antigenicity of the gelatin molecule. By an entirely different method, 
namely the hemagglutination technique  (22)  which can measure as little as 
0.006 ttg. antibody per ml. serum, Grabar has recently confirmed the findings 
presented  here concerning the presence of significant amounts of antibodies 
to gelatin in normal sera (23). In view of the data presented here and the con- 
firmation by Grabar, some of the criteria for antigenicity of a protein molecule 
will have to be revised. 
Since gelatin or its derivatives have been proposed as plasma expanders, the 
question arises as to the advisability of employing a plasma substitute which 
is antigenic. Under proper medical supervision two good reactors  to gelatin 
were given reinjections of gelatin. No untoward reactions were observed at all. 
It is worth recalling here an idea proposed by Grabar that some antibody 
molecules may not necessarily be functioning as part of a protective mechanism 
but rather as a  transporting system involved in carrying materials to sites for 
further reaction (24).  That the antibodies to gelatin are instrumental in the 
metabolism of gelatin and/or collagen is quite plausible. 
The findings presented here and in the next paper which show that many 
normal sera have antibodies to gelatin make available immunochemical tech- 
niques  for studying problems  connected  with  the  structure of the gelatins, 
soluble collagens  (procoliagens),  and insoluble collagens from many species. 
Applications of these techniques to a  study of "collagen" disease can also be 
visualized.  Investigations  along  these  lines  are  contemplated. 512  ANTIGENICITY  OF OXYPOLYGELATIN  AND GELATIN IN MAN 
SUMMARY 
It has been demonstrated that there are normally occurring antibodies to 
gelatin in human sera. Immunization with gelatin can in many cases increase 
the antibody level. The presence of these antibodies does not result in cu- 
taneous reactions of the wheal and erythema type after injection of antigen. 
Many  of  the  properties  of  the  gelatin-antigelatin reaction  and  the  pre- 
cipitates formed are those of a truly specific antigen-antibody aggregate. 
Explanations have been advanced both as to  the possible  sources of  the 
gelatin antibody and its significance. 
The author wishes to thank Dr. Arthur Cherkin of Don Baxter, Incorporated, and the 
staff of the National Research Council Subcommittee on Shock for making available the 
materials used in  this study. 
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